RiboTargets Competitors

At SCYNEXIS, we are committed to improving outcomes for patients living with severe, progressive, and underserved rare diseases. Around the world, patients with severe, progressive rare diseases continue to face limited therapeutic options and significant unmet medical need, creating meaningful opportunity for differentiated innovation. We are focused on advancing a portfolio of highly differentiated, clinical‑stage assets targeting the underlying biology of severe rare diseases. Our programs are designed around the needs of patients facing limited options, with a focus on delivering clinically meaningful benefit. Guided by deep scientific expertise and disciplined drug development execution, we strive to improve outcomes for patients who urgently need better solutions. (NASDAQ: SCYX)

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others.

MGB Biopharma’s focus is to further develop their completely new class of anti-infective medicine, starting with antibiotics based on Minor Groove Binder (MGBs) compounds. The Company’s experienced management team have dedicated their initial focus to the development of a new class of small molecules, with specific antibacterial activity against susceptible and resistant bacteria. In providing a new class of drug to the field of antibacterial resistance, based on a truly novel mechanism of action, MGB Biopharma are unique, in that a truly new class and novel MoA was last seen in the year 2000. There are many drugs used to treat bacterial infections, and generally they belong to classes which have been in use for several decades. Due to the rise in resistant strains of bacteria, several of these drugs are becoming less and less effective. The Company’s progress has been rapid, and our lead drug candidate, MGB-BP-3, is currently in Phase I clinical safety studies, which will reach completion at the end of 2015. MGB-BP-3 is just the first in our new exciting class of anti-infectives. MGB Biopharma commenced operations in 2010, and is funded by a syndicate of some of Scotland’s leading business angels, in co-operation with Scottish Enterprise.